FILE PHOTO: The exterior of the European Medicines Agency is seen in Amsterdam, Netherlands, December 18, 2020. REUTERS/Piroschka van de Wouw/File Photo
(Reuters) – The European medicines regulator said on Monday it would hold a meeting this week on the information gathered into whether the AstraZeneca COVID-19 vaccine contributed to thromboembolic events in those inoculated.
While its investigation is ongoing, the European Medicines Agency remains of the view that the benefits of the AstraZeneca vaccine in preventing COVID-19 outweigh the risks of side effects. (bit.ly/3trmufB)
Reporting by Yadarisa Shabong in Bengaluru; Editing by Shounak Dasgupta
Our Standards: The Thomson Reuters Trust Principles.
Tiiny AI’s Pocket Lab makes headlines at CES 2026 with a pocket size personal AI…
Study by fäm Luxe highlights how Dubai has built ecosystem designed to attract and retain…
At CES 2026 in Las Vegas, ACEMAGIC unveiled its latest AI-powered Mini PC lineup
Technology is rapidly reshaping the gaming industry, driving a fundamental shift in how games are…
All applications will be treated with strict confidentialityAccess Multimedia Content LONDON, United Kingdom, January 23,…
Be part of the global dialogue shaping the future of work at the Global Labor…